A public economics framework is used to consider how pharmaceuticals should be priced when at least some of the research and development incentive comes from sales revenues. Familiar techniques of public finance are used to relax some of the restrictions implied in the standard use of Ramsey pricing. Under the more general model, poor countries should not necessarily cover even their own marginal costs, and the pricing structure is not related to...
Exibir mais
DETALHES
-
2005/01/01
-
Artigo de revista
-
77482
-
1
-
1
-
2013/05/23
-
Disclosed
-
Financing pharmaceutical innovation : how much should poor countries contribute?
-
marginal cost of production
DOWNLOADS
COMPLETAR RELATÓRIO
Versão oficial do documento (pode conter assinaturas, etc.)
-
Total Downloads** : 203
*A versão do texto é um OCR incorreto e está incluído unicamente em benefício de usuários com conectividade lenta.